IMVT

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

High

17.060

Open

15.030

VWAP

16.26

Vol

4.33M

Mkt Cap

2.86B

Low

14.965

Amount

70.36M

EV/EBITDA(TTM)

Total Shares

146.05M

1.98B

EV/OCF(TTM)

P/S(TTM)

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

-0.720

-2.64%

-0.724

-4.77%

-0.743

+16.17%

Estimates Revision

Stock Price

Go Up

+8.16%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 37.83 USD with a low forecast of 18.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

3 Hold

0 Sell

Strong Buy

Current: 16.700

Low

18.00

Averages

37.83

High

57.00

Current: 16.700

Low

18.00

Averages

37.83

High

57.00

JPMorgan

Overweight -> Overweight

downgrade

$40 -> $37

2025-08-12

Reason

JPMorgan

Price Target

$40 -> $37

2025-08-12

downgrade

Overweight -> Overweight

Reason

JPMorgan lowered the firm's price target on Immunovant to $37 from $40 and keeps an Overweight rating on the shares. The firm updated the company's model post earnings.

BofA

Jason Gerberry

Buy

downgrade

$33 -> $30

2025-08-12

Reason

BofA

Jason Gerberry

Price Target

$33 -> $30

2025-08-12

downgrade

Buy

Reason

BofA analyst Jason Gerberry lowered the firm's price target on Immunovant to $30 from $33 and keeps a Buy rating on the shares. The firm updated its model for fiscal Q1 financials, calling the quarterly update "mainly a reiteration of timelines for key R&D programs." Following the update, the firm pushed back the MG and CIDP launches to 2027-plus to reflect 1402 trial timelines, the analyst noted.

Citi

Samantha Semenkow

Buy

downgrade

$58 -> $57

2025-08-11

Reason

Citi

Samantha Semenkow

Price Target

$58 -> $57

2025-08-11

downgrade

Buy

Reason

Citi analyst Samantha Semenkow lowered the firm's price target on Immunovant to $57 from $58 and keeps a Buy rating on the shares. The firm, which continues to believe IMVT-1402 has "blockbuster potential" across multiple indications, updated its model to account for fiscal Q1 actuals. The firm's lower target is driven by higher expected operating expenses related to IMVT-1402 clinical development, the analyst noted.

UBS

Ashwani Verma

Neutral

maintain

$17 -> $18

2025-07-28

Reason

UBS

Ashwani Verma

Price Target

$17 -> $18

2025-07-28

maintain

Neutral

Reason

UBS analyst Ashwani Verma raised the firm's price target on Immunovant to $18 from $17 and keeps a Neutral rating on the shares. UBS remains cautious on the Immunovant story due to limited/no catalyst until 2027, as well as a financing overhang, the analyst tells investors in a research note.

Goldman Sachs

Neutral

maintain

$18

2025-07-10

Reason

Goldman Sachs

Price Target

$18

2025-07-10

maintain

Neutral

Reason

Goldman Sachs resumed coverage of Immunovant with a Neutral rating and $18 price target. The firm sees limited downside but also a challenging regulatory backdrop for the company.

H.C. Wainwright

Buy

downgrade

$51 -> $35

2025-05-30

Reason

H.C. Wainwright

Price Target

$51 -> $35

2025-05-30

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Immunovant to $35 from $51 and keeps a Buy rating on the shares. The target cut reflects the company's data readouts in 2027, with an expected potential launch in 2028.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunovant Inc (IMVT.O) is -5.03, compared to its 5-year average forward P/E of -11.53. For a more detailed relative valuation and DCF analysis to assess Immunovant Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.53

Current PE

-5.03

Overvalued PE

-2.57

Undervalued PE

-20.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.40

Current EV/EBITDA

-3.77

Overvalued EV/EBITDA

-0.67

Undervalued EV/EBITDA

-18.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.41

Current PS

0.00

Overvalued PS

58.33

Undervalued PS

-39.50